News Related to Undifferentiated Pleomorphic Sarcoma

Related coverage linked through entity extraction aliases.

Iovance Biotherapeutics Reports Q4 Revenue Beat, FDA Fast Track for Lung Cancer

Feb 26, 2026

Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.

Morning Dosing of Cancer Immunotherapy Extends Survival in Lung Cancer Trial

Feb 13, 2026

A randomized trial of 210 advanced lung cancer patients found that administering checkpoint inhibitor immunotherapy in the morning nearly doubled progression-free survival and extended overall survival by nearly a year compared to later-day dosing.